2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. CDK

CDK

Cyclin dependent kinase

CDK

Related Products

PDF 1.19 MB

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.

There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.

CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

CDK Isoform Specific Products:

CDK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N7045R
    Isosilybin B (Standard)
    		Inhibitor
    Isosilybin B (Standard) is the analytical standard of Isosilybin B (HY-N7045). This product is intended for research and analytical applications. Isosilybin B is a flavonolignan. Isosilybin B can be isolated from Silybum marianum. Isosilybin B can regulate cell cycle-related proteins (e.g., reduce cyclins (D3, D1, A, E), Cdk4, Cdk2, Cdc25A), and activate Caspases (Caspase-9 and Caspase-3). Isosilybin B can promote Apoptosis, reduce androgen receptor (AR) and PSA. Isosilybin B has anticancer activity against prostate cancer.
    Isosilybin B (Standard)
  • HY-151408
    CDK1-IN-4
    		Inhibitor
    CDK1-IN-4 (10d) is a selective CDK1 inhibitor with IC50s of 44.52, 624.93 and 135.22 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN4 inhibits the growth of cancer cells by affecting cell cycle. CDK1-IN-4 can be used for the research of cancer.
    CDK1-IN-4
  • HY-B0402R1
    Amantadine in Methanol (Standard)
    		Inhibitor
    Amantadine in Methanol (Standard) is the solution of Amantadine (Standard). This product is intended for research and analytical applications. Amantadine (1-Adamantanamine) is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine also has anti-orthopoxvirus and anticancer activity. Amantadine can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research[4].
    Amantadine in Methanol (Standard)
  • HY-176718
    VEGFR-2-IN-69
    		Inhibitor
    VEGFR-2-IN-69 (Compound 5A) is a dual inhibitor of VEGFR-2 and Telomerase, which upregulates the expression of caspase 3, caspase 8 and caspase 9, while downregulating CDK-2, CDK-4 and CDK-6. VEGFR-2-IN-69 exhibits an IC50 of 15.46 µM against HCT116 cells.
    VEGFR-2-IN-69
  • HY-170442
    CDK2-IN-37
    		Inhibitor
    CDK2-IN-37 (COMPOUND 2) is a cyclin-dependent kinase (CDK2) inhibitor with anti-cancer activity.
    CDK2-IN-37
  • HY-158377
    CDK8/19-IN-2
    		Inhibitor
    CDK8/19-IN-2 (compound 12) is an orally active and potent cyclin-dependent kinase 8/19 (CDK8 and CDK19) inhibitor, with IC50 values of 2.08 and 2.49 nM, respectively. CDK8/19-IN-2 can be used for acute myeloid leukemia (AML), breast cancer, and lymphoma research.
    CDK8/19-IN-2
  • HY-30237S
    (R)-Roscovitine-d7
    		Inhibitor
    (R)-Roscovitine-d7 (Seliciclib-d7; CYC202-d7) is deuterium-labeled (R)-Roscovitine (HY-30237).
    (R)-Roscovitine-d<sub>7</sub>
  • HY-164553
    ZSQ836
    		Inhibitor
    ZSQ836 is an orally active dual covalent inhibitor of CDK12/CDK13, with an EC50 value of 32 nM against CDK12. ZSQ836 can induce apoptosis and exhibit anticancer activity in vivo. ZSQ836 can be used in the study of ovarian cancer.
    ZSQ836
  • HY-50940R
    AT7519 (Standard)
    		Inhibitor
    AT7519 (Standard) is the analytical standard of AT7519. This product is intended for research and analytical applications. AT7519 (AT7519M) as a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.
    AT7519 (Standard)
  • HY-N0805R
    Alisol B 23-acetate (Standard)
    		Inhibitor
    Alisol B 23-acetate (Standard) is the analytical standard of Alisol B 23-acetate (HY-N0805). This product is intended for research and analytical applications. Alisol B 23-acetate is an orally active prototerpane-type triterpenoid. Alisol B 23-acetate can be isolated from Alisma orientalis. Alisol B 23-acetate induces Apoptosis, promotes ROS generation, downregulates CDK4/6, MMP-2/9, upregulates cleaved PARP, activates FXR and inhibits Syk. Alisol B 23-acetate has anti-inflammatory and hepatoprotective activities. Alisol B 23-acetate protects the kidney from ischemia-reperfusion injury. Alisol B 23-acetate has anticancer activity against ovarian cancer, colon cancer, lung cancer, and gastric cancer. Alisol B 23-acetate can be used in the study of atherosclerosis and allergic asthma.
    Alisol B 23-acetate (Standard)
  • HY-119120
    JTK-101
    		Inhibitor
    JTK-101 is a selective HIV inhibitor. JTK-101 selectively reduces HIV-1 mRNA synthesis by inhibiting Tat cofactors, including CDK9 and cyclin T1, thereby suppressing the transcriptional activity of HIV-1. JTK-101 may be used in the field of anti-HIV virus research.
    JTK-101
  • HY-10012R
    AZD-5438 (Standard)
    		Inhibitor
    AZD-5438 (Standard) is the analytical standard of AZD-5438. This product is intended for research and analytical applications. AZD-5438 is a potent CDK1, CDK2, and CDK9 inhibitor, with IC50s of 16 nM, 6 nM, and 20 nM in cell-free assays, respectively. AZD-5438 shows less inhibition activity against GSK3β, CDK5 and CDK6 .
    AZD-5438 (Standard)
  • HY-80013B
    (E/Z)-THZ1 dihydrochloride
    		Inhibitor
    (E/Z)-THZ1 dihydrochloride is a selective inhibitor of CDK7 with an IC50 of 3.2 nM. (E/Z)-THZ1 dihydrochloride has antiproliferative effect.
    (E/Z)-THZ1 dihydrochloride
  • HY-160643
    CDK2-IN-27
    		Inhibitor
    CDK2-IN-27 (compound 1) is a potent CDK2 inhibitor with IC50 values of <10, >10-20 nM for CDK2/cyclin E1, CDK2/cyclin B1, respectively.
    CDK2-IN-27
  • HY-115729A
    (R)-PROTAC CDK9 ligand-1
    		Degrader
    (R)-PROTAC CDK9 ligand-1 (Compound 19.4) is a CDK9-targeting degrader that can be used to synthesize PROTAC with antitumor activity.
    (R)-PROTAC CDK9 ligand-1
  • HY-13231R
    CDK9-IN-1 (Standard)
    		Inhibitor
    CDK9-IN-1 (Standard) is the analytical standard of CDK9-IN-1. This product is intended for research and analytical applications. CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection, with an IC50 of 39 nM for CDK9/CycT1, extracted from reference, compound 87.
    CDK9-IN-1 (Standard)
  • HY-18299AR
    Purvalanol A (Standard)
    		Inhibitor
    Purvalanol A (Standard) is the analytical standard of Purvalanol A. This product is intended for research and analytical applications. Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC50s of 4, 70, 35, 850, 75 nM, resepctively.
    Purvalanol A (Standard)
  • HY-15154R
    NG 52 (Standard)
    		Inhibitor
    NG 52 (Standard) is the analytical standard of NG 52. This product is intended for research and analytical applications. NG 52 is a potent, cell-permeable, selective, ATP-compatible and orally active Cdc28p and Pho85p kinase inhibitor with IC50s of 7 μM and 2 μM, respectively. NG 52 also inhibits the activity of phosphoglycerate kinase 1 (PGK1) with an IC50 of 2.5 μM. NG 52 is inactive against yeast kinases Kin28p, Srb10, and Cak1p.
    NG 52 (Standard)
  • HY-N1431A
    Tabersonine hydrochloride
    		Inhibitor
    Tabersonine hydrochloride is a selective, orally active NLRP3 inhibitor. Tabersonine hydrochloride directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine hydrochloride also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, PI3K/Akt, and p38 MAPK signaling pathways. Tabersonine hydrochloride can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine hydrochloride is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer.
    Tabersonine hydrochloride
  • HY-108420
    INK4C-IN-2
    		Activator 98.10%
    INK4C-IN-2 (Compound 40) is the inhibitor for INK4C (also known as p18) and the activator for CDK4/6. INK4C-IN-2 increases the number and expansion capacity of mouse and human hematopoietic stem cells (HSCs) with EC50 of 5.21 nM, promotes the self-renewal and multilineage differentiation of HSCs. INK4C-IN-2 improves the expansion and long-term hematopoietic reconstruction ability of HSCs in mouse bone marrow transplantation model.
    INK4C-IN-2
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
CDK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.